Protagonist Therapeutics, Inc. — Form 10-Q Summary
Business context and reporting period
Protagonist Therapeutics is a clinical-stage biopharmaceutical company developing constrained peptide-based therapies for hematology and gastroenterology. The filing covers the three and six months ended June 30, 2019, with comparisons to the corresponding 2018 periods. The company had no approved products or product sales and operated as a single segment.
Key financial metrics
| Metric | Three months ended June 30, 2019 | Six months ended June 30, 2019 |
|---|---|---|
| License and collaboration revenue | $(8.2) million | $(6.6) million |
| Research and development expense | $19.4 million | $31.8 million |
| General and administrative expense | $3.9 million | $7.6 million |
| Loss from operations | $(31.4) million | $(46.1) million |
| Net loss | $(29.2) million | $(43.3) million |
| Net loss per share | $(1.18) | $(1.77) |
| Operating cash flow | Not separately provided for the quarter | $(13.0) million |
At June 30, 2019, cash and cash equivalents were $71.1 million, available-for-sale securities were $55.0 million, and total cash, cash equivalents and available-for-sale securities were approximately $126.1 million. Total assets were $148.1 million, total liabilities were $63.8 million, and stockholders’ equity was $84.3 million. The company reported no outstanding debt. Accumulated deficit was $183.8 million.
Cash used in investing activities was $9.1 million, primarily reflecting purchases of marketable securities and property and equipment. Financing activities provided $11.0 million, including $10.5 million of net proceeds from an at-the-market equity offering. Cash, cash equivalents and restricted cash declined by $11.1 million during the first six months, ending at $71.6 million.
Material changes versus the prior comparable period
- Revenue declined from $11.7 million to negative $8.2 million in the second quarter and from $22.5 million to negative $6.6 million for the first six months. The change was driven primarily by a $9.4 million cumulative catch-up revenue reduction related to the May 2019 amendment of the Janssen agreement.
- The Janssen amendment expanded research and development activities for second-generation IL-23 receptor compounds and triggered a $25.0 million payment received during the second quarter. The estimated transaction price under the agreement increased to approximately $109.2 million at June 30, 2019.
- Second-quarter research and development expense increased 9% year over year, driven by higher spending on PN-943 and PTG-300 and a reversal of Australian research and development tax incentive reductions. Six-month research and development expense decreased 4% because lower PTG-100 and PTG-200 spending more than offset increased PN-943 and PTG-300 spending.
- Net loss increased substantially from $8.7 million to $29.2 million for the quarter and from $16.3 million to $43.3 million for the six-month period.
- The company adopted ASC 842 on January 1, 2019, recognizing a right-of-use asset and lease liabilities. At June 30, 2019, operating lease liabilities totaled $7.8 million.
- Shares outstanding increased to 24.97 million at June 30, 2019 from 23.19 million at December 31, 2018, primarily reflecting ATM issuance and exercise of exchange warrants.
Guidance, outlook, commentary and risks
Management stated that existing cash, cash equivalents and available-for-sale securities were expected to fund operations and capital requirements for at least the next 12 months based on the current operating plan. The company also stated that substantial additional capital will be required to advance clinical development and potentially commercialize its candidates. Future financing may involve equity dilution, debt covenants, unfavorable licensing terms or reduced research activity.
- PTG-300: Phase 2 beta-thalassemia dosing began in the first quarter of 2019. Preliminary results were expected in the fourth quarter of 2019 and topline results in the first half of 2020. A polycythemia vera Phase 2 study was planned for the third quarter of 2019, with hereditary hemochromatosis and investigator-sponsored myelodysplastic syndrome studies targeted for early 2020.
- PTG-200: Janssen submitted a U.S. IND for Crohn’s disease in the second quarter; the filing was approved in July 2019. A Phase 2 Crohn’s disease study was expected to begin in the fourth quarter of 2019.
- PN-943: Phase 1 development continued, with a Phase 2 ulcerative colitis proof-of-concept study anticipated in early 2020.
- Important risks include clinical-trial failure or delay, patient enrollment challenges, regulatory nonapproval, manufacturing and supply constraints, reliance on Janssen and other third parties, intellectual-property disputes, competition, reimbursement uncertainty and the need for additional financing.
- The company’s PTG-100 Phase 2 ulcerative colitis study had previously been discontinued for futility; management later reported that independent review identified human error in the original endoscopy readings and signals of potential efficacy. PTG-100 was replaced by PN-943 as the development candidate.
- There were no material legal proceedings reported, and management concluded that disclosure controls and procedures were effective at the reasonable-assurance level.
Most important facts for investors to verify
- Reconcile the negative reported collaboration revenue with the $9.4 million cumulative catch-up reduction and assess the assumptions underlying the Janssen transaction price and percentage-of-completion model.
- Confirm the timing, scope and results of the planned PTG-300, PTG-200 and PN-943 clinical milestones.
- Assess the company’s cash runway against rising clinical expenditures and the stated need for substantial additional capital.
- Review the economic impact, termination rights, cost-sharing obligations, milestones and royalty terms in the amended Janssen agreement.
- Monitor equity dilution: the company sold $10.5 million of stock through the ATM during the first six months and an additional 1.2 million shares for $15.0 million net proceeds from July 1 through July 31, 2019.
- Evaluate the sensitivity of future results to clinical outcomes, regulatory decisions, third-party execution and potential termination or reduced activity by Janssen.